A pilot trial assessing the effect of fish oil on leptin and adiponectin levels in overweight/obese individuals.
A pilot trial assessing the effect of marine lipids on leptin and adiponectin levels in overweight/obese individuals.
Centre for Integrative Clinical and Molecular Medicine, University of Queensland
48 participants
Nov 8, 2010
Interventional
Conditions
Summary
Obesity is a global epidemic. It is associated with a high burden of chronic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and some cancers. Obesity and CVD progression have been associated with altered levels of biologically active proteins secreted by adipocytes, including the hormones adiponectin and leptin. This study aims to assess the effect of a high dose marine lipid supplement [dose: 4000mg per day for 8 weeks] on plasma adiponectin and leptin levels in overweight and obese individuals.
Eligibility
Inclusion Criteria1
- Participants will have a BMI of 25 or greater and be generally healthy.
Exclusion Criteria8
- Concurrent use of other medications or investigational products;
- Weight loss of more than 10% body weight within the last six months;
- Active substance abuse (alcohol or drug dependency);
- Breast feeding or pregnancy;
- Smoking;
- Allergies to fish oil supplements;
- Major Health Conditions;
- Concomitant use of anticoagulants or statin medications (Pravastatin).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment with commercially available marine lipid preparation at a dose of 4 x 1000mg capsules per day (each capsule contains 300mg EPA, 200mg DHA) for a period of 8 weeks
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000983000